Pinnacle Wealth Planning Services Inc. Invests $273,000 in IDEXX Laboratories, Inc. $IDXX

Pinnacle Wealth Planning Services Inc. acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 509 shares of the company’s stock, valued at approximately $273,000.

Several other large investors have also recently bought and sold shares of the stock. Mutual of America Capital Management LLC raised its holdings in shares of IDEXX Laboratories by 79.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock worth $8,160,000 after purchasing an additional 8,609 shares in the last quarter. Private Advisor Group LLC grew its position in IDEXX Laboratories by 16.5% during the 1st quarter. Private Advisor Group LLC now owns 2,088 shares of the company’s stock worth $877,000 after purchasing an additional 295 shares in the last quarter. Kestra Private Wealth Services LLC grew its holdings in shares of IDEXX Laboratories by 4.7% during the first quarter. Kestra Private Wealth Services LLC now owns 2,014 shares of the company’s stock valued at $846,000 after buying an additional 91 shares in the last quarter. J.W. Cole Advisors Inc. grew its stake in IDEXX Laboratories by 44.7% during the 1st quarter. J.W. Cole Advisors Inc. now owns 3,994 shares of the company’s stock valued at $1,677,000 after acquiring an additional 1,234 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in shares of IDEXX Laboratories by 2.6% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 6,338 shares of the company’s stock worth $2,662,000 after purchasing an additional 159 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the sale, the director directly owned 262 shares of the company’s stock, valued at approximately $169,600.46. This represents a 89.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Stock Up 4.0%

NASDAQ:IDXX opened at $697.10 on Thursday. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $735.00. The stock’s fifty day simple moving average is $653.54 and its 200-day simple moving average is $593.39. The firm has a market capitalization of $55.66 billion, a P/E ratio of 58.04, a P/E/G ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company’s revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on IDXX shares. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research note on Monday, November 3rd. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, November 13th. Morgan Stanley upped their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Piper Sandler reaffirmed a “neutral” rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Finally, UBS Group lifted their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $730.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.